|Denaro||403,46 x 1100|
|Lettera||403,66 x 1100|
|Min-Max giorno||394,50 - 406,26|
|Intervallo di 52 settimane||260,42 - 555,77|
|Beta (5 anni mensile)||0,97|
|Rapporto PE (ttm)||90,64|
|Prossima data utili||27 apr 2021|
|Rendimento e dividendo (forward)||N/D (N/D)|
|Data ex dividendo||N/D|
|Stima target 1A||403,38|
Full year revenue should grow between 25% and 28% to $4.05 billion, higher than prior $3.91 billion estimates.
Illumina shares jumped 11.87% Friday after the genomic sequence company delivered impressive quarterly results.
Illumina Inc, a global leader in genomics, said on Monday that it would acquire Grail, a healthcare company whose mission is focused on early detection of multi-cancer, for cash and stock consideration of $8 billion.